


UTILITY PATENT APPLICATION TRANSMITTAL		<i>(only for new nonprovisional applications under 37 CFR 1.53(b))</i>	
		<i>Attorney Docket No.</i>	CEN 5017USNP
		<i>First Inventor</i>	Marian Nakada
		<i>Title</i>	USE OF EMMPRIN ANTAGONISTS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH EXCESSIVE ANGIOGENESIS
		<i>Express Mail Label No.</i>	EU556305404US
APPLICATION ELEMENTS		ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
<p><i>See MPEP Chapter 600 concerning utility patent application contents.</i></p> <p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) (submit an original and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status.</p> <p>3. <input checked="" type="checkbox"/> Specification [Total Pages 30] (Preferred arrangement set forth below)</p> <ul style="list-style-type: none"> - Descriptive Title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R&D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure <p>4. <input checked="" type="checkbox"/> Drawing(s)(35 USC 113) [Total Sheets 9]</p> <p>5. Oath or Declaration [Total Pages 39]</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed)</p> <p>i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p> <p>18. <input type="checkbox"/> If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:</p> <p><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-Part (CIP) of prior application No.: , filed .</p> <p>Prior application information: Examiner Group Art Unit:</p> <p>For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.</p>		<p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)</p> <p>a. <input type="checkbox"/> Computer Readable Form (CRF)</p> <p>b. <input type="checkbox"/> Specification Sequence Listing on: <ul style="list-style-type: none"> i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper </p> <p>c. <input type="checkbox"/> Statement verifying identity of above copies</p> <p>ACCOMPANYING APPLICATION PARTS</p> <p>9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</p> <p>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney (when there is an assignee)</p> <p>11. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>13. <input type="checkbox"/> Preliminary Amendment</p> <p>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)</p> <p>16. <input type="checkbox"/> Request and Certifications under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.</p> <p>17. <input type="checkbox"/> Other</p>	
19. CORRESPONDENCE ADDRESS			
<p><input checked="" type="checkbox"/> Customer Number or Bar Code Label 000027777 or <input type="checkbox"/> Correspondence Address below</p> <p>Name: Philip S. Johnson, Esq.</p> <p>Address: Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 USA</p>			
20. TELEPHONE CONTACT			
<p>Please direct all telephone calls or telefaxes to Kenneth J. Dow at:</p> <p>Telephone: (610) 651-7422 Fax: (610) 651-6940</p>			
21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
NAME	Kenneth J. Dow		Reg. No. 32890
SIGNATURE			
DATE	March 24, 2004		

17510 USPTO 10/808699

032504

032504
22783

U.S.PTO

FEE TRANSMITTAL

Complete if Known	
Application Number	
Filing Date	March 24, 2004
First Named Inventor	Marian Nakada
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 5017 USNP

FEE CALCULATION**CLAIMS AS FILED**

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE \$750.00
TOTAL CLAIMS	18 - 20 =	0	x 18.00	\$ 0.00
INDEPENDENT CLAIMS	4- 3 =	1	x 84.00	\$ 84.00
MULTIPLE DEPENDENT CLAIMS	<input type="checkbox"/>	N/A	\$280.00	
			TOTAL FEES	\$ 834.00

METHOD OF PAYMENT

- Please charge Deposit Account No. 10-0750/CEN5017USNP/KD in the amount of \$834.00. Three copies of this sheet are enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/CEN5017USNP/KD. Three copies of this sheet are enclosed.

SUBMITTED BY:		Complete (if applicable)	
Typed or Printed Name	Kenneth J.Dow		Reg. No. 32,890
Signature		Date: March 24, 2004	Deposit Account No. 10-0750-CEN 5017USNP

DOCKET NO. CEN 5017USNP

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

Applicant: Marian Nakada
Li Yan
Yi Tang

For : USE OF EMMPRIN ANTAGONISTS FOR THE TREATMENT OF
DISEASES ASSOCIATED WITH EXCESSIVE ANGIOGENESIS.

Express Mail Certificate

"Express Mail" mailing number: EU556305404US


Date of Deposit: MARCH 24, 2004

I hereby certify that this complete application, including specification pages, claims, and informal drawings, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop: Patent Application, the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

A Combined Declaration and Power of Attorney will be submitted to the United States Patent and Trademark Office upon receipt of the U.S. Serial Number for this patent application.

KENNETH J. DOW

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)